I've been doing some review of the literature on Boswellia. After doing the review, I've begun to take it.
I'm not an expert by any means but, given what I have read, I'd be taking Boswellia (anda the "5-Loxin" trademarked brand in particular) if I had a cancer diagnosis.
Try googling "Boswellia cancer apoptosis" and be prepared to spend a few hours reading to see what I mean.
I will post a few studies about Boswellia and cancer each day for the next several days. If there are only enough funds such that a choice must be made between COQ10 and Boswellia then choose Boswellia.
There are literally dozens, maybe over a hundred studies, demonstrating the efficacy of Boswellia for cancer treatment.
I'll post a bit later about why I believe the 5-Loxin trademark brand is the one to go with.
It's hard for me to imagine that there could be a more significantly beneficial supplement than Boswellia that has not been discussed in depth at ImmInst.org.
You don't need to wait for me to post these studies. Google "boswellia cancer apoptosis" and see for yourself.
***************************************************
J Neurooncol. 2007 Mar;82(1):91-3. Epub 2006 Sep 26
A lipoxygenase inhibitor in breast cancer brain metastases.
Flavin DF.
Foundation for Collaborative Medicine and Research, Greenwich, CT 06831, USA. Dana_FK@hotmail.com
The complication of multiple brain metastases in breast cancer patients is a life threatening condition with limited success following standard therapies. The arachidonate lipoxygenase pathway appears to play a role in brain tumor growth as well as inhibition of apoptosis in in-vitro studies. The down regulation of these arachidonate lipoxygenase growth stimulating products therefore appeared to be a worthwhile consideration for testing in brain metastases not responding to standard therapy. Boswellia serrata, a lipoxygenase inhibitor was applied for this inhibition. Multiple brain metastases were successfully reversed using this method in a breast cancer patient who had not shown improvement after standard therapy. The results suggest a potential new area of therapy for breast cancer patients with brain metastases that may be useful as an adjuvant to our standard therapy.
***************
J Immunol. 2006 Mar 1;176(5):3127-40
Acetyl-11-keto-beta-boswellic acid potentiates apoptosis, inhibits invasion, and abolishes osteoclastogenesis by suppressing NF-kappa B and NF-kappa B-regulated gene expression.
Takada Y, Ichikawa H, Badmaev V, Aggarwal BB.
Cytokine Research Section, Department of Experimental Therapeutics, University of Texas M. D. Anderson Cancer Center, Houston, TX 77030, USA.
Acetyl-11-keto-beta-boswellic acid (AKBA), a component of an Ayurvedic therapeutic plant Boswellia serrata, is a pentacyclic terpenoid active against a large number of inflammatory diseases, including cancer, arthritis, chronic colitis, ulcerative colitis, Crohn's disease, and bronchial asthma, but the mechanism is poorly understood. We found that AKBA potentiated the apoptosis induced by TNF and chemotherapeutic agents, suppressed TNF-induced invasion, and inhibited receptor activator of NF-kappaB ligand-induced osteoclastogenesis, all of which are known to require NF-kappaB activation. These observations corresponded with the down-regulation of the expression of NF-kappaB-regulated antiapoptotic, proliferative, and angiogenic gene products. As examined by DNA binding, AKBA suppressed both inducible and constitutive NF-kappaB activation in tumor cells. It also abrogated NF-kappaB activation induced by TNF, IL-1beta, okadaic acid, doxorubicin, LPS, H2O2, PMA, and cigarette smoke. AKBA did not directly affect the binding of NF-kappaB to the DNA but inhibited sequentially the TNF-induced activation of IkappaBalpha kinase (IKK), IkappaBalpha phosphorylation, IkappaBalpha ubiquitination, IkappaBalpha degradation, p65 phosphorylation, and p65 nuclear translocation. AKBA also did not directly modulate IKK activity but suppressed the activation of IKK through inhibition of Akt. Furthermore, AKBA inhibited the NF-kappaB-dependent reporter gene expression activated by TNFR type 1, TNFR-associated death domain protein, TNFR-associated factor 2, NF-kappaB-inducing kinase, and IKK, but not that activated by the p65 subunit of NF-kappaB. Overall, our results indicated that AKBA enhances apoptosis induced by cytokines and chemotherapeutic agents, inhibits invasion, and suppresses osteoclastogenesis through inhibition of NF-kappaB-regulated gene expression.
***************
Anticancer Res. 2002 Sep-Oct;22(5):2853-62
Cytostatic and apoptosis-inducing activity of boswellic acids toward malignant cell lines in vitro.
Hostanska K, Daum G, Saller R.
Departmment of Internal Medicine, University Hospital Zürich, Rämistrasse 100, 8091 Zürich, Switzerland. katarina.hostanska@access.unizh.ch
Boswellic acids from frankincense were indentified as the active compounds which inhibit leukotriene biosynthesis, 5-lipoxygenase and exert antiproliferative activity toward a variety of malignant cells. Because of the relevance for the clinical application, we tested the ethanolic extract of Boswellia serrata gum resin containing a defined amount of boswellic acids for its cytotoxic, cytostatic and apoptotic activity on five leukemia (HL-60, K 562, U937, MOLT-4, THP-1) and two brain tumor (LN-18, LN-229) cell lines by WST-1 assay and flow cytometry. The Boswellia serrata extract induced dose-dependent antiproliferative effects on all human malignant cells tested with GI50 values (extract concentration producing 50% cell growth inhibition) between 57.0 and 124.1 micrograms/ml. In three haematological cell lines (K562, U937, MOLT-4) the effect of total extract expressed in GI50 was 2.8-, 3.3- and 2.3-times more potent (p < 0.05) than pure 3-O-acetyl-11-keto-beta-boswellic acid (AKBA). Morphological changes after 24-27 hours and the detection of apoptotic cells by AnnexinV-binding and/or by the detection of propidium iodide-labelled DNA with flow cytometry, confirmed the apoptotic cell death. The results of this study suggest the effectiveness of Boswellia serrata extract with defined content of boswellic acids.
Edited by wccaguy, 28 July 2008 - 12:48 PM.